Los Angeles Capital Management LLC Purchases 100 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Los Angeles Capital Management LLC increased its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 3.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,394 shares of the medical instruments supplier’s stock after buying an additional 100 shares during the quarter. Los Angeles Capital Management LLC owned 0.06% of Mesa Laboratories worth $448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of MLAB. FMR LLC raised its stake in shares of Mesa Laboratories by 34.1% during the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock worth $51,000 after acquiring an additional 100 shares in the last quarter. Quantbot Technologies LP purchased a new position in Mesa Laboratories in the 3rd quarter worth $70,000. Amalgamated Bank lifted its stake in Mesa Laboratories by 6.5% in the third quarter. Amalgamated Bank now owns 1,588 shares of the medical instruments supplier’s stock worth $206,000 after purchasing an additional 97 shares during the last quarter. Captrust Financial Advisors purchased a new stake in Mesa Laboratories during the third quarter valued at about $207,000. Finally, Berry Wealth Group LP boosted its position in Mesa Laboratories by 5.3% during the fourth quarter. Berry Wealth Group LP now owns 1,657 shares of the medical instruments supplier’s stock valued at $219,000 after buying an additional 83 shares during the period. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Stock Down 2.8 %

Shares of Mesa Laboratories stock opened at $135.44 on Tuesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.53 and a current ratio of 0.71. Mesa Laboratories, Inc. has a 52-week low of $83.68 and a 52-week high of $155.12. The company’s 50 day moving average price is $139.89 and its 200-day moving average price is $129.46. The stock has a market capitalization of $735.98 million, a price-to-earnings ratio of -2.93 and a beta of 0.83.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.41 by $0.66. Mesa Laboratories had a negative net margin of 104.92% and a positive return on equity of 30.23%. Equities research analysts forecast that Mesa Laboratories, Inc. will post 8 EPS for the current year.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Friday, February 28th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date of this dividend is Friday, February 28th. Mesa Laboratories’s payout ratio is -1.38%.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, November 13th.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.